Cellular Immunotherapies for Multiple Myeloma: Current Status, Challenges, and Future Directions

Multiple myeloma (MM) remains incurable due to relapse, although the use of proteasome inhibitors, immunomodulatory drugs, CD38-targeting antibodies, and autologous stem cell transplantation (auto-SCT) significantly improve the clinical outcomes of patients with newly diagnosed MM. In recent years,...

Descripción completa

Detalles Bibliográficos
Autores principales: Yan, Zhi-Ling, Wang, Yue-Wen, Chang, Ying-Jun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2022
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9098731/
https://www.ncbi.nlm.nih.gov/pubmed/35103936
http://dx.doi.org/10.1007/s40487-022-00186-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9098731/
https://www.ncbi.nlm.nih.gov/pubmed/35103936
http://dx.doi.org/10.1007/s40487-022-00186-4

Ejemplares similares